Get started
Nurix Therapeutics, Inc.Nurix Therapeutics, Inc.Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

NRIX trade ideas

Gilead tie-up ,Big Pharma confidence,massive upside if trials OK 🧪 Pipeline Progress (as of latest update): NX-2127 & NX-5948 in Phase 1 🔬 NX-1607: Promising early clinical data in solid tumors Multiple preclinical programs in immuno-oncology and autoimmune space Down ~80% from highs (2021 biotech bubble burst 😬) Consolidating near lows — potential bottom fishing zone 🐟 High short interest = possible squeeze setup 🔥 Speculative high-reward biotech. Great long-term potential if pipeline delivers. Suitable for risk-tolerant investors only. Not for the faint-hearted 🧠⚡
NASDAQ:NRIXLong
by ramkdlr
Nurix Therapeutics (NRIX) Analysis Clinical Milestone: Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win." Strategic Collaborations: Nurix is also advancing collaborations with major pharma companies. It is set to nominate a development candidate with Sanofi this year, positioning it for substantial breakthroughs. Additionally, Gilead Sciences extended its research collaboration with Nurix by two years, highlighting Nurix's robust R&D capabilities. Investment Outlook: Bullish Outlook: We are bullish on NRIX above the $15.00-$16.00 range. Upside Potential: With a target set at $30.00-$31.00, investors should consider Nurix's promising clinical results and strategic partnerships as key drivers for potential stock growth. 📊🧬 Monitor Nurix Therapeutics for promising investment opportunities! #NRIX #Biotech 📈💊
NASDAQ:NRIXLong
by Richtv_official
Nurix TherapeuticsNurix Therapeutics witnessed a strong rebound in yesterday's session, violating the last peak at 18.12, and remaining above this level in today's session, will confirm this breakout, which will confirm the current uptrend, with higher targets near 19.92 - 21.53 - 24 - 25.46 - 27.30. The stop-loss lies below 17.28. the indicators are heading toward the positive side, which confirms the mentioned positive scenario. The information and publications are not intended to be or constitute any financial, investment, commercial, or other types of advice or recommendations provided.
NASDAQ:NRIXLong
by Gehad_Abouelela